Antonio Rodriguez-Calero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antonio Rodriguez-Calero has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
- Mark A. Rubin
Department for BioMedical Research, University of Bern, Bern, Switzerland
77 shared publications - Cory Abate-Shen
Columbia University, New York, New York
51 shared publications - Juan Martín Arriaga
Department of Molecular Pharmacology and Therapeutics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, USA
50 shared publications - Michael M. Shen
Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
47 shared publications - Alessandro Vasciaveo
Department of Systems Biology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA
34 shared publications - Andrea Califano
Department of Systems Biology, Columbia University, New York, USA
34 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Additional analyses related to Figure 3.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Additional analyses related to Figure 3.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Additional analyses related to Figure 4
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Additional analyses related to Figure 4
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Characteristics of GEMM cohort used and raw quantification of ATAD2 expression
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Characteristics of GEMM cohort used and raw quantification of ATAD2 expression
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Oligonucleotides used in this Study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Oligonucleotides used in this Study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Additional analyses of MYC regulation of ATAD2.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Additional analyses of MYC regulation of ATAD2.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Additional analysis of ATAD2 expression in prostate cancer.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from ATAD2 Drives Prostate Cancer Progression to Metastasis
Additional analysis of ATAD2 expression in prostate cancer.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from ATAD2 Drives Prostate Cancer Progression to Metastasis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from ATAD2 Drives Prostate Cancer Progression to Metastasis
- Open Access
- 28 May 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (7)
A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer
Although most prostate tumors are relatively indolent, advanced disease can progress to aggressive, often lethal variants, including neuroendocrine prostate cancer (NEPC). To identify drivers of aggressive prostate cancer, we used Sleeping Beauty (SB) transposon mutagenesis in a mouse model having prostate-specific loss of Pten and Tp53 (NPp53 mice). Compared with control NPp53-SB(−) mice, experimental NPp53-SB(+) mice developed more aggressive tumors with increased metastasis. Notably, NPp53-SB(+) mice exhibited NEPC phenotypes with transcriptomic features that recapitulate human NEPC. Analysis of recurrent common insertion sites (CIS) and associated genes (CIS genes) identified genes differentially expressed between NEPC and non-NEPC tumors. Analysis of NEPC-enriched CIS genes by cross-species integration of genomic and transcriptomic data prioritized sirtuin 1 (Sirt1) as a candidate mechanistic determinant of NEPC. Gain- and loss-of-function studies in human prostate cancer cells and mouse NEPC organoids confirmed that SIRT1 promotes NEPC, while pharmacological inhibition suppresses it. Thus, integration of cross-species analyses with an unbiased forward genetic screen uncovered novel drivers of NEPC.
- 28 May 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (7)
Open AccessA forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer
Although most prostate tumors are relatively indolent, advanced disease can progress to aggressive, often lethal variants, including neuroendocrine prostate cancer (NEPC). To identify drivers of aggressive prostate cancer, we used Sleeping Beauty (SB) transposon mutagenesis in a mouse model having prostate-specific loss of Pten and Tp53 (NPp53 mice). Compared with control NPp53-SB(−) mice, experimental NPp53-SB(+) mice developed more aggressive tumors with increased metastasis. Notably, NPp53-SB(+) mice exhibited NEPC phenotypes with transcriptomic features that recapitulate human NEPC. Analysis of recurrent common insertion sites (CIS) and associated genes (CIS genes) identified genes differentially expressed between NEPC and non-NEPC tumors. Analysis of NEPC-enriched CIS genes by cross-species integration of genomic and transcriptomic data prioritized sirtuin 1 (Sirt1) as a candidate mechanistic determinant of NEPC. Gain- and loss-of-function studies in human prostate cancer cells and mouse NEPC organoids confirmed that SIRT1 promotes NEPC, while pharmacological inhibition suppresses it. Thus, integration of cross-species analyses with an unbiased forward genetic screen uncovered novel drivers of NEPC.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S11 from OncoLoop: A Network-Based Precision Cancer Medicine Framework
Figure S1: Genomic alterations in prostate cancer represented in the GEMMs (related to Fig. 2). Figure S2: Additional phenotypic analyses of the GEMMs (related to Fig. 2). Figure S3: Phenotypic analysis of allograft and organoid models (related to Fig. 2). Figure S4: Additional transcriptomic analyses of the GEMMs (related to Fig. 3). Figure S5: Analyses of AR activity in GEMMS (related to Fig. 3). Figure S6: Regulatory sub-networks of the GEMM clusters (related to Fig. 3). Figure S7. MR-match of prostate cancer cells lines to human PCa (related to Figs. 5). Figure S8. Drug perturbation protein activity profiles from DU145 cells (related to Figs. 5, 6, 7). Figure S9. LNCaP Pharmacotyping to patients and GEMMs (related to Figs. 5). Figure S10: Additional validation of drug candidates (related to Figs 6, 7). Figure S11: Additional validation of drug candidates (related to Figs 6).
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S11 from OncoLoop: A Network-Based Precision Cancer Medicine Framework
Figure S1: Genomic alterations in prostate cancer represented in the GEMMs (related to Fig. 2). Figure S2: Additional phenotypic analyses of the GEMMs (related to Fig. 2). Figure S3: Phenotypic analysis of allograft and organoid models (related to Fig. 2). Figure S4: Additional transcriptomic analyses of the GEMMs (related to Fig. 3). Figure S5: Analyses of AR activity in GEMMS (related to Fig. 3). Figure S6: Regulatory sub-networks of the GEMM clusters (related to Fig. 3). Figure S7. MR-match of prostate cancer cells lines to human PCa (related to Figs. 5). Figure S8. Drug perturbation protein activity profiles from DU145 cells (related to Figs. 5, 6, 7). Figure S9. LNCaP Pharmacotyping to patients and GEMMs (related to Figs. 5). Figure S10: Additional validation of drug candidates (related to Figs 6, 7). Figure S11: Additional validation of drug candidates (related to Figs 6).
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from OncoLoop: A Network-Based Precision Cancer Medicine Framework
Supplementary Table 6. OncoLoop summary table
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from OncoLoop: A Network-Based Precision Cancer Medicine Framework
Supplementary Table 6. OncoLoop summary table